Search our Innovation Portfolio

Nettle, is a Class-IIa, CE-marked, drug-free, hormone-free, Bluetooth-controlled wearable transcranial direct current stimulation (tDCS) device developed by women at Samphire Neuroscience, and is tailored to women’s needs. Nettle provides non-invasive stimulation to both the motor cortex (to alleviate physical pain) and the prefrontal cortex (to improve symptoms of mood disorders). Use of Nettle during the final two weeks of the menstrual cycle has been shown to relieve pain and low mood associated with dysmenorrhea (painful menstrual cramps), premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD).

Women are 50% more likely than men to be misdiagnosed or diagnosed late and 35% less likely to receive life-saving treatment. LightHearted AI has developed LightScope, a breakthrough technology that can reduce the heart valve disease (HVD) diagnosis gap.

LightScope uses laser light to captures heart sounds, ECG and Blood Pressure contactlessly in one single scan. AI algorithms analyse this data to diagnose several conditions, including HVD. LightScope is accurate (>90% accuracy for HVD), requires no training and is cost-effective, addressing underdiagnosis and late diagnosis issues.

Signatur Biosciences is developing OncoSignatur Breast (OSB), a decentralised, cost-effective breast cancer prognostic test that addresses the limitations of current centralised gene expression tests. OSB enables efficient local profiling of 21 genes predictive of chemotherapy benefit, eliminating overseas sample shipping. This reduces costs, accelerates turnaround times, and improves test accessibility. OSB provides healthcare systems with a decentralised solution for personalised care, helping thousands of women avoid unnecessary chemotherapy and its debilitating side effects. This grant will serve as a key catalyst for SigBio, advancing OSB from its prototype status to a fully developed, user-friendly kit.